Catalio Capital Management
New York, New York, United StatesFounded 2020
Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public, and credit markets. It backs breakthrough biomedical technology companies founded by scientist-entrepreneurs, spanning drugs, devices, diagnostics, data, tools, and healthcare services.
51% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (5 deals in the last 12 months vs 16 prior). Average disclosed round size is $100.5M (across 99 rounds with reported amounts).
Portfolio
83
Fund Size
$400M
Top Stage
Series A
Last 12 Mo
5
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
106 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Somethings | Series A | $19.2M | Feb 2026 |
 Aviceda | Series C | — | Jan 2026 |
 ProSomnus | Unknown | $38M | Jan 2026 |
| CClaris Bio | Series B | $57M | Jan 2026 |
 Claris | Series B | $118M | Jan 2026 |
| AAviceda Therapeutics | Unknown | $207.5M | Jan 2026 |
 Medra | Series A | $52M | Dec 2025 |
| KKailera | Series B | $600M | Oct 2025 |
 Cartography | Series B | $67M | Oct 2025 |
 Leo Cancer Care | Series C | $40M | Sep 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Visby Medical | Growth | $55M | Jun 2025 |
| VVisby | Series E | $65M | Jun 2025 |
 GlycoEra | Series B | $130M | May 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
| IImbria | Unknown | $57.5M | Apr 2025 |
| LLILA | Seed | $200M | Mar 2025 |
 atai Life Sciences | Series C | $125M | Feb 2025 |
 Perceive Bio | Series A | $15M | Feb 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 AtaiBeckley | Series C | — | Jan 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
 Character Bio | Series B | $93M | Jan 2025 |
| IImbria | Series B | $57.5M | Jan 2025 |
| VVolastra | Seed | $44M | Jan 2025 |
Page 1 of 5
Top Co-Investors
Alexandria Venture Investments15 shared
RA Capital Management14 shared
OrbiMed12 shared
Eli Lilly and Company12 shared
General Catalyst11 shared
Mubadala Ventures11 shared
T. Rowe Price10 shared
Sofinnova Partners10 shared
F-Prime Capital9 shared
Novo Holdings A/S9 shared
ARCH Venture Partners9 shared
GV9 shared
Polaris Partners9 shared
Logos Capital8 shared
Fidelity Investments8 shared
Gaingels8 shared
SR One7 shared
HBM Healthcare Investments7 shared
Rock Springs Capital7 shared
Samsara BioCapital7 shared
Last updated: 7 October 2026